Research Papers:
Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1951 views | HTML 2650 views | ?
Abstract
Xuejing Lin1,*, Zhangxiao Peng1,*, Xiaohui Fu2,*, Chunying Liu1, Yang Xu1, Weidan Ji1, Jianhui Fan1, Lei Chen1, Lin Fang3, Yao Huang2, Changqing Su1,3
1Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China
2Department of Biliary Tract Surgery, Eastern Hepatobiliary Surgical Hospital, Second Military Medical University, Shanghai 200438, China
3Jiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical College, Xuzhou 221002, China
*These authors have contributed equally to this work
Correspondence to:
Changqing Su, email: [email protected]
Yao Huang, email: [email protected]
Keywords: VOSL, hepatocellular carcinoma, epithelial growth factor receptor, signaling, xenograft model
Received: June 20, 2016 Accepted: October 19, 2016 Published: October 28, 2016
ABSTRACT
Hepatocellular carcinoma (HCC) treatment remains lack of effective chemotherapeutic drugs, therefore, discovering novel anti-HCC drugs is a very attractive and urgent task. In this study, we reported VOSL (volatile oil from Saussurea lappa root) exhibits potent therapeutic effect on SMMC-7721 xenografts without obvious side effects. In the in vitro experiments, VOSL inhibited HCC cell proliferation by arresting cell cycle at S and G2/M phases, and induced HCC cell apoptosis by activating the Caspase3 pathway. VOSL also decreased the capability of HCC cell migration and invasion through MMP-9 depression. Moreover, mechanistic study indicated that VOSL can act as an epithelial growth factor receptor (EGFR) inhibitor to suppress EGFR activation and then to suppress its downstream MEK/P38 and PI3-K/Akt pathways. These results suggested that VOSL may be a novel anti-HCC drug candidate.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12962